<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02069561</url>
  </required_header>
  <id_info>
    <org_study_id>EPAUC/2013</org_study_id>
    <nct_id>NCT02069561</nct_id>
  </id_info>
  <brief_title>Effects of Eicosapentaenoic Acid on Subjects at High Risk for Colorectal Cancer</brief_title>
  <acronym>EPAUC</acronym>
  <official_title>Effects of Eicosapentaenoic Acid on Molecular, Metabonomics and Intestinal Microbiota Changes, in Subjects With Long-standing Inflammatory Bowel Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IRCCS Azienda Ospedaliero-Universitaria di Bologna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IRCCS Azienda Ospedaliero-Universitaria di Bologna</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to test Eicosapentaenoic acid's effects on markers relevant to&#xD;
      colorectal carcinogenesis, RNA and DNA profiles, and the possibility that Eicosapentaenoic&#xD;
      Acid treatment might be associated with changes of the gut microbiota and metabolomic&#xD;
      profiles in patients with long-standing ulcerative colitis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2014</start_date>
  <primary_completion_date type="Actual">August 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes of RNA profiles (gene expression and micro RNA) from baseline</measure>
    <time_frame>baseline and at 3 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes of DNA methylation profiles</measure>
    <time_frame>baseline and 3 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in cell proliferation</measure>
    <time_frame>baseline and 3 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes of apoptosis</measure>
    <time_frame>baseline and 3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes of circulating cytokines from baseline</measure>
    <time_frame>baseline and 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of membrane fatty acid composition from baseline</measure>
    <time_frame>baseline and 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of metabolomic profiles from baseline</measure>
    <time_frame>baseline and 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Microbiota composition from baseline</measure>
    <time_frame>baseline and 3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Ulcerative Colitis</condition>
  <arm_group>
    <arm_group_label>Eicosapentaenoic Acid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with long-standing ulcerative colitis and meeting the inclusion criteria will receive 2 g/day of Eicosapentaenoic Acid as a supplement for 90 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal controls</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Five patients undergoing screening colonoscopy and polypectomy using biopsy forceps. Six biopsies of healthy mucosa will be collected at the time of colonoscopy. Faeces, urine and blood samples will be collected prior to performing colonoscopy. The samples will serve as healthy reference for the basic studies.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Eicosapentaenoic Acid</intervention_name>
    <description>Twenty patients with long-standing ulcerative colitis undergoing the usual colonoscopic surveillance + biopsy sampling will be recruited. At entry six extra biopsy samples will be collected from the colon. We will also collect blood (for serum, plasma and red cells isolation), urine and stools. Subjects will then receive 2 g/day of Eicosapentaenoic Acid (ALFA ™, SLA Pharma AG, Switzerland) as a supplement for 90 days. At the end of the study each subject will undergo sigmoidoscopy for the collection of 6 biopsies. Blood, urine and stools will be obtained prior to the procedure.</description>
    <arm_group_label>Eicosapentaenoic Acid</arm_group_label>
    <other_name>ALFA ™</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Arm: experimental&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with ulcerative colitis (diagnosed based on clinical criteria, endoscopic and&#xD;
             histological) lasting over 8 years, with no clinical activity (SCCAI = 0), and in&#xD;
             stable treatment (without any change in treatment in the previous 3 months) with&#xD;
             mesalamine, immunomodulators and / or biologics.&#xD;
&#xD;
          -  Baseline fecal calprotectin&gt; 150 micrograms / g.&#xD;
&#xD;
          -  Signed informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients receiving systemic steroids in the two months prior to study entry.&#xD;
&#xD;
          -  Patients taking concomitant warfarin or other blood thinners.&#xD;
&#xD;
          -  Known or suspected hypersensitivity to eicosapentaenoic acid/omega 3.&#xD;
&#xD;
          -  Women who are pregnant or of childbearing age who do not accept the use of&#xD;
             contraceptive methods specified in the study (oral contraception, IUDs) and&#xD;
             breastfeeding women.&#xD;
&#xD;
          -  Patients with severe medical conditions that, in the opinion of the investigator,&#xD;
             contraindicate the patient's participation in the study.&#xD;
&#xD;
          -  Changes of treatments and / or use of experimental drugs within 3 months before&#xD;
             inclusion in the study.&#xD;
&#xD;
          -  Use of Probiotics&#xD;
&#xD;
        Arm: no intervention&#xD;
&#xD;
        Inclusion criteria&#xD;
&#xD;
          -  Subjects undergoing screening colonoscopy within the regional colorectal cancer&#xD;
             screening programme&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
          -  Polypectomy with biopsy forceps.&#xD;
&#xD;
        Exclusion criteria&#xD;
&#xD;
          -  HBV-positive, HCV-positive, HIV-positive or otherwise affected by infectious diseases&#xD;
&#xD;
          -  Subjects undergoing chemo and radiation therapy within six months prior to surgery&#xD;
&#xD;
          -  Patients receiving systemic steroid in the two months prior to study entry&#xD;
&#xD;
          -  Patients undergoing antibiotic therapy within three months prior to the study&#xD;
&#xD;
          -  Patients treated with probiotics&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Luigi Ricciardiello, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Azienda Ospedaliero Universitaria Policlinico S.Orsola Malpighi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria Policlinico Sant'Orsola Malpighi</name>
      <address>
        <city>Bologna</city>
        <state>BO</state>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <study_first_submitted>February 19, 2014</study_first_submitted>
  <study_first_submitted_qc>February 20, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 24, 2014</study_first_posted>
  <last_update_submitted>September 17, 2015</last_update_submitted>
  <last_update_submitted_qc>September 17, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 18, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>IRCCS Azienda Ospedaliero-Universitaria di Bologna</investigator_affiliation>
    <investigator_full_name>Luigi Ricciardiello</investigator_full_name>
    <investigator_title>Associate Professor of Gastroenterology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis, Ulcerative</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

